Clonidine

可乐定

Report date: 2022/01/14 13:23:58

Base Information

Drug NameClonidine
Drug Alias Name可乐定缓释剂Clonidine micropelletsClonidine extended release (Sollis Therapeutics)clonidinumclonidine +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImidazoline receptor agonistsAdrenergic receptors alpha-2 agonists
TargetsAdrenergic receptors alpha-2Imidazoline receptor
Therapy Area/IndicationsStress Disorders, Post-TraumaticOpioid-Related DisordersChills +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyEgypt
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSollis Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversidad Simón BolívarZagazig UniversitySollis Therapeutics Inc
Inactive CompaniesAtlantic Health System IncCharite University, Berlin, GermanyUniversity Of Maryland, Baltimore
Active IndicationsOpioid-Related DisordersChillsPostoperative Nausea and Vomiting +[6] 
Inactive IndicationsStress Disorders, Post-TraumaticRadiculopathyMusculoskeletal Diseases

Other Information

ATC CodeC02AC01N02CX02S01EA04
Related LinksN/A